The Latest Updates from ReSPECT Clinical Trials

Come join us at the American Association of Neurological Surgeons (AANS) Annual Meeting in Chicago, IL next week! Visit our booth to learn about our #clinicaltrials for #patients with recurrent #glioblastoma, leptomeningeal #metastases, & pediatric #braincancer...

"Plus Therapeutics' commitment to revolutionizing cancer treatment extends beyond this latest award. With $23 million in active awards support, the company is at the forefront of targeted radiotherapeutic research. Moreover, ongoing trials, including ReSPECT-GBM for...

Join some of the Plus Therapeutics team at the Head for the Cure 5K - North Texas on May 4th! They will be out supporting the local community, cancer research, and "Defeating Brain Cancer Step by Step." We hope to see you there 🏃🏃‍♂️🏃‍♀️ Event information:...

#ICYMI: Plus Therapeutics added Dr. Andrew Brenner to our management team. Dr. Brenner will provide substantial input on the Company’s central nervous system cancer development programs while continuing to maintain his academic practice and laboratory. Full Press...

#ICYMI : "Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst...Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target. Justin Walsh has given his Buy rating due to a...

We would like to officially welcome Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. to the Plus Therapeutics Management Team! “As we prepare for the future, Plus is substantially strengthening its management in key areas such as cancer biology,...

We are pleased to introduce Frank Gonzalez Rodriguez as Senior Clinical Trial Associate at Plus Therapeutics! He is looking forward to being on the sponsor side of our clinical trials and part of our clinical operations team....

April is dedicated to raising awareness for cancer prevention and treatment throughout the US. 🎗️ At Plus Therapeutics, we seek to help patients and clinicians find safe, lasting solutions for treating rare and difficult-to-treat cancers....

We want to thank all of the #doctors and Principal Investigators we get to work with to help us run our #clinicaltrials and provide #treatment options for #patients! They all are great supporters of our mission to solve the toughest challenges in #oncology 🩺...